April 28, 2021New England Journal of Medicine247 citationsOpen Access
Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety in patients with NDD-CKD. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; PRO2TECT ClinicalTrials.gov numbers, NCT02648347 and NCT02680574.).